| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.86B | 26.69B | 24.22B | 18.54B | 13.57B | 7.34B |
| Gross Profit | 8.69B | 9.53B | 7.46B | 5.78B | 4.17B | 3.02B |
| EBITDA | 3.05B | 3.84B | 2.51B | 2.03B | 1.57B | 1.26B |
| Net Income | 1.18B | 1.70B | 1.39B | 1.15B | 892.41M | 667.02M |
Balance Sheet | ||||||
| Total Assets | 32.95B | 30.47B | 24.02B | 21.96B | 23.02B | 12.34B |
| Cash, Cash Equivalents and Short-Term Investments | 7.89B | 7.67B | 4.66B | 5.23B | 3.65B | 3.47B |
| Total Debt | 15.90B | 12.13B | 8.42B | 8.67B | 11.64B | 3.19B |
| Total Liabilities | 18.83B | 16.12B | 11.56B | 10.64B | 13.22B | 4.46B |
| Stockholders Equity | 13.53B | 13.78B | 12.27B | 11.09B | 9.80B | 7.88B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 185.31M | 73.83M | 3.78B | -8.16B | -3.82B |
| Operating Cash Flow | 0.00 | 435.30M | 452.64M | 4.36B | -7.31B | -3.57B |
| Investing Cash Flow | 0.00 | -1.37B | -376.36M | -427.07M | -1.64B | -253.80M |
| Financing Cash Flow | 0.00 | 1.94B | -554.26M | -3.13B | 9.31B | 3.28B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ¥49.26B | 6.41 | ― | 3.59% | 15.82% | 22.32% | |
76 Outperform | ¥57.87B | 34.25 | ― | 2.10% | 27.87% | 40.85% | |
69 Neutral | ¥56.70B | 7.44 | ― | 6.09% | 8.07% | 12.06% | |
66 Neutral | ¥45.88B | 10.75 | ― | 5.84% | 67.46% | 68.56% | |
66 Neutral | ¥45.14B | 37.89 | ― | 0.50% | -8.33% | -36.89% | |
65 Neutral | $2.17B | 12.19 | 3.79% | 4.94% | 3.15% | 1.96% | |
65 Neutral | ¥46.75B | 7.40 | ― | 2.47% | 33.64% | -0.28% |
SRE Holdings Corporation’s FY2025 2Q financial results highlight its focus on integrating technology into life and healthcare sectors. The company’s operations span across real estate, finance, and IT, offering AI cloud tools and consulting services. This strategic positioning aims to enhance its market presence and provide innovative solutions to stakeholders.
The most recent analyst rating on (JP:2980) stock is a Hold with a Yen2874.00 price target. To see the full list of analyst forecasts on SRE Holdings Corp. stock, see the JP:2980 Stock Forecast page.
SRE Holdings Corporation reported a significant decline in its financial performance for the six months ending September 30, 2025, with net sales dropping by 20.3% and profits decreasing sharply compared to the previous year. Despite the downturn, the company maintains a positive outlook for the fiscal year ending March 31, 2026, projecting a 31.1% increase in net sales and a 30.8% rise in profit attributable to owners, indicating a potential recovery and growth in its operations.
The most recent analyst rating on (JP:2980) stock is a Hold with a Yen2874.00 price target. To see the full list of analyst forecasts on SRE Holdings Corp. stock, see the JP:2980 Stock Forecast page.
SRE Holdings Corporation announced the issuance of paid stock options to its directors and employees, aiming to align their interests with the company’s long-term performance goals. This move is intended to enhance corporate value and shareholder value by setting performance-based criteria for exercising these options, which could result in a reasonable share dilution of approximately 4.5% if all options are exercised.
The most recent analyst rating on (JP:2980) stock is a Hold with a Yen2874.00 price target. To see the full list of analyst forecasts on SRE Holdings Corp. stock, see the JP:2980 Stock Forecast page.
SRE Holdings Corporation announced that its wholly owned subsidiary, MEDIX Co, Ltd., will distribute surplus dividends amounting to 600,600,000 yen to the parent company. This dividend income will be recorded as non-operating income in SRE Holdings’ non-consolidated financial results, with no impact on the consolidated financial results for the fiscal year ending March 31, 2026.
The most recent analyst rating on (JP:2980) stock is a Hold with a Yen3591.00 price target. To see the full list of analyst forecasts on SRE Holdings Corp. stock, see the JP:2980 Stock Forecast page.